This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2023 Jun 29;141(26):3130-3132.

doi: 10.1182/blood.2023020525.

IL-34: a novel differentiation therapy for AML?

Nainita Roy¹, Christopher Y Park¹

Affiliations

PMID: 37383007
DOI: 10.1182/blood.2023020525

Free article

Editorial

IL-34: a novel differentiation therapy for AML?

Nainita Roy et al. Blood. 2023.

Free article

. 2023 Jun 29;141(26):3130-3132.

doi: 10.1182/blood.2023020525.

Authors

Nainita Roy¹, Christopher Y Park¹

Affiliation

¹ New York University Grossman School of Medicine.

PMID: 37383007
DOI: 10.1182/blood.2023020525

No abstract available

PubMed Disclaimer

Comment on

TREM2 acts as a receptor for IL-34 to suppress acute myeloid leukemia in mice.
Xie X, Zhang W, Xiao M, Wei T, Qiu Y, Qiu J, Wang H, Qiu Z, Zhang S, Pan Y, Mao L, Li Y, Guo B, Yang W, Hu Y, Hu S, Gong Y, Yang J, Xiao G, Zhang Y, Bai X. Xie X, et al. Blood. 2023 Jun 29;141(26):3184-3198. doi: 10.1182/blood.2022018619. Blood. 2023. PMID: 37001042 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems
Medical
- MedlinePlus Health Information